Hypogammaglobulinemia, a new risk factor for hepatitis B virus reactivation : about two cases.
|Journal||Volume 86 - 2023|
|Issue||Fasc.3 - Case reports|
|Author(s)||F. de Leuze 1, V. Havelange 2, M-A. van Dievoet 3, Y. Horsmans 1, G. Dahlqvist 1|
VIEW FREE PDF
(1) Hepatogastroenterology unit, Cliniques Universitaires Saint-Luc, Brussels, Belgium
(2) Hematology unit, Cliniques Universitaires Saint-Luc, Brussels, Belgium
(3) Laboratory department, Cliniques universitaires Saint-Luc, Brussels, Belgium
Reactivation of the hepatitis B virus (HBV) with immunosuppressive status has been well established, mainly due to medications such as immunosuppressive therapy like cytotoxic chemotherapy, rituximab and biologic therapy, immunosuppression after solid and bone-marrow transplantation or long-term corticosteroids therapy. We report here two cases of HBV reactivation due to global hypogammaglobulinemia. Regular HBV serologic screening and PCR for HBV-DNA should be applied for each patient with primary immunosuppressive status and history of chronic HBV infection. The necessity of a preemptive treatment remains debated.
Keywords: Hepatitis B reactivation, immunosuppression, hypogammaglobulinemia, common variable immunodeficiency.
|The authors declare that they have no conflict of interest.|
© Acta Gastro-Enterologica Belgica.